|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.SE |
First Approval Date01 Jan 2012 |
Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation
National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63 days gestational age through a multi-center prospective non interventional study design.
100 Clinical Results associated with Linepharma International Ltd.
0 Patents (Medical) associated with Linepharma International Ltd.
100 Deals associated with Linepharma International Ltd.
100 Translational Medicine associated with Linepharma International Ltd.